Asset profile
Duloxetine · Cymbalta
Small molecule
Evidence outlook
Approved: Diabetic Peripheral Neuropathic Pain
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
16 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 15 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Duloxetine (Cymbalta): this drug | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | ||
| Ammoxetine | Phase 3 | Small molecule | Serotonin/norepinephrine transporter | ||
| Capsaicin (Qutenza) | Approved | Small molecule | TRPV1 (transient receptor potential vanilloid 1) channel | ||
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | ||
| Suzetrigine | Approved | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| Tapentadol | Approved | Small molecule | Mu-opioid receptor and norepinephrine transporter (NET) | ||
| Crisugabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| Mirogabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| HL-1186 | Phase 2/3 | Small molecule | — | ||
| HRS-2129 | Phase 2/3 | Small molecule | — | ||
| JMKX000623 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| LY4065967 | Phase 2 | Small molecule | Angiotensin II type 2 receptor (AT2R) (antagonist) | ||
| NRD135S.E1 | Phase 2 | Small molecule | — | ||
| Pilavapadin | Phase 2 | Small molecule | AP2-associated kinase 1 (AAK1) | ||
| Pirenzepine (topical) | Phase 2 | Small molecule | Muscarinic acetylcholine receptor (M3), Muscarinic M1 receptor (antagonist) | ||
| VX-993 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 |
…and 1 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(24 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (6)
December 2026 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (11)
January 2027 (1)
What to watch
March 2027 (3)
What to watch
What to watch
What to watch
May 2027 (2)
June 2027 (2)
July 2027 (2)
November 2027 (1)
What to watch
2028 (5)
March 2028 (1)
What to watch
April 2028 (1)
What to watch
June 2028 (1)
What to watch
August 2028 (1)
What to watch
December 2028 (1)
What to watch
2030 (1)
February 2030 (1)
What to watch
2031 (1)
September 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.